Clinical Trials for Kidney Cancer

Pilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD) in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Newly diagnosed multiple myeloma patients with significant renal impairment (CrCl <60 mL/min and/or dialysis) receive four 28-day cycles of subcutaneous daratumumab-hyaluronidase (anti‑CD38) plus bortezomib, cyclophosphamide, and dexamethasone, with outcomes focused on depth of hematologic response and renal recovery. Planned enrichment for approximately 50% African American participants; post-induction therapy follows standard practice (ASCT if eligible or additional Dara-CyBorD, then maintenance with lenalidomide plus SC daratumumab).

ClinicalTrials.gov ID: NCT06142396

A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm study for adolescents and adults with advanced measurable HLRCC-associated RCC or sporadic/non-HLRCC papillary RCC (prior VEGF therapy allowed, but no prior bevacizumab or PD-1/PD-L1 in the advanced setting), including patients with treated/stable brain mets. Treatment combines bevacizumab (anti-VEGF), erlotinib (EGFR TKI), and atezolizumab (anti–PD-L1) given in 21-day cycles until progression/toxicity, aiming to improve response and disease control.

ClinicalTrials.gov ID: NCT04981509

A Phase II Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab for Patients With Monoclonal Gammopathy of Renal Significance (MGRS)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with MGRS due to plasma cell dyscrasia, including NDMM with cast nephropathy or other biopsy-proven MGRS lesions (excluding AL amyloidosis), impaired renal function/proteinuria, and no prior anti–plasma cell therapy receive CyBorD plus subcutaneous daratumumab. Daratumumab is an anti‑CD38 monoclonal antibody; treatment includes 8 induction cycles with optional ASCT and, if ineligible, maintenance bortezomib/dexamethasone every other week plus daratumumab every 4 weeks.

ClinicalTrials.gov ID: NCT06083922

Phase I/II Study of Seleno-L Methionine (SLM) in Sequential Combination With Fixed Doses and Schedules of Axitinib and Pembrolizumab (SAP) in Locally Advanced and Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with untreated, locally advanced or metastatic clear cell RCC (ECOG 0–1) receive standard pembrolizumab (anti–PD-1) plus axitinib (VEGFR TKI) with the addition of oral seleno-L-methionine (an organic selenium agent proposed to modulate redox stress and sensitize tumors), after a 2-week SLM run-in. Excludes untreated CNS mets and significant cardiovascular risks; primary aims are safety/MTD of SLM and preliminary response rates.

ClinicalTrials.gov ID: NCT05363631

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic RCC and at least one measurable untreated or locally progressive brain metastasis (asymptomatic/mildly symptomatic, largely steroid-independent; ECOG 0–2) receive nivolumab (PD‑1 inhibitor) plus ipilimumab (CTLA‑4 inhibitor) with cabozantinib (MET/VEGFR/AXL TKI), with maintenance nivolumab/cabozantinib; prior systemic therapy allowed if no prior CTLA‑4, cabozantinib, or MET inhibitor. Primary aim is to improve intracranial PFS; a safety lead-in may omit ipilimumab if excess toxicity.

ClinicalTrials.gov ID: NCT05048212

A Phase 1b Study to Assess the Effects of Belzutifan on 89Zr-DFO-girentuximab Uptake as a Surrogate to Determine CAIX Tumor Expression in Patients With Clear Cell Renal Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with advanced/metastatic clear cell RCC after progression on prior immune checkpoint therapy (≥2 prior regimens) receive belzutifan monotherapy (HIF‑2α inhibitor) with paired 89Zr‑DFO‑girentuximab PET imaging to assess changes in CAIX expression at 4 weeks. Includes patients with measurable disease, KPS ≥60%, and allows controlled viral infections and stable brain metastases.

ClinicalTrials.gov ID: NCT07179770

A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial involves adults with unresectable or metastatic advanced solid tumors who have progressed on prior treatments or are candidates for pembrolizumab, combining pembrolizumab, which targets the PD-1 receptor to enhance immune response, with a personalized neoantigen peptide vaccine designed to stimulate an individualized immune attack against tumor-associated proteins.

ClinicalTrials.gov ID: NCT05269381

A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial involves patients with advanced or metastatic solid tumors expressing Nectin-4, including urothelial carcinoma, triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer, who have exhausted standard therapy options. It evaluates LY4052031, an antibody-drug conjugate that targets Nectin-4 to deliver a topoisomerase I inhibitor, aiming to assess its safety, tolerability, and efficacy in these patients.

ClinicalTrials.gov ID: NCT06465069

A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy in Patients with Locally Advanced or Metastatic Cancers Following One or More Prior Therapies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial involves patients with advanced or metastatic solid tumors, such as melanoma and non-small cell lung cancer, who have had prior therapies, evaluating the safety and efficacy of Alintegimod, an integrin-targeting agent, combined with ipilimumab and nivolumab.

ClinicalTrials.gov ID: NCT06362369

A Phase 1, First-in-Human, Open-Label, Multi-Center, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LB-LR1109 for the Treatment of Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: The trial is for adult patients with advanced or metastatic non-small cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, or malignant melanoma who have no remaining standard treatment options, and it evaluates the safety, tolerability, and dosing of the investigational drug LB-LR1109, administered intravenously.

ClinicalTrials.gov ID: NCT06332755